Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis

BACKGROUND: The BOLT study for sonidegib, a Hedgehog pathway inhibitor (HHI) approved for patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy, used modified Response Evaluation Criteria in Solid Tumors (mRECIST) for laBCC tumor evaluation. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutzmer, Ralf, Robert, Caroline, Loquai, Carmen, Schadendorf, Dirk, Squittieri, Nicholas, Arntz, Ramon, Martelli, Serena, Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603490/
https://www.ncbi.nlm.nih.gov/pubmed/34798846
http://dx.doi.org/10.1186/s12885-021-08968-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603490/
https://www.ncbi.nlm.nih.gov/pubmed/34798846
http://dx.doi.org/10.1186/s12885-021-08968-1

Ejemplares similares